文献速递血栓与止血

利用抗独特型单克隆抗体在艾美赛珠单抗存在下常规测定凝血因子VIII活性和抑制物滴度

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
PubMed 文献 · J Thromb Haemost · 2018-05-27

本研究旨在建立可靠的APTT法在艾美赛珠单抗存在下测定凝血因子VIII(FVIII)。制备两种抗艾美赛珠单抗抗独特型单克隆抗体(rcAQ8和rcAJ540),联合使用可完全中和艾美赛珠单抗对APTT、FVIII活性和抑制物滴度测定的干扰,实现准确测定。

要点

  • 两种抗艾美赛珠单抗抗独特型单抗联合可中和艾美赛珠单抗活性。
  • 艾美赛珠单抗存在时FVIII活性被高估,加入抗独特型单抗可完全纠正。
  • 艾美赛珠单抗干扰FVIII抑制物滴度测定,加入抗独特型单抗后可准确评估。

核心结论

  • 在标准一步法凝血试验中体外加入抗艾美赛珠单抗单克隆抗体可防止艾美赛珠单抗干扰,实现FVIII活性和抑制物滴度的准确测定。

研究设计与样本

  • 使用无抑制物或有抑制物的血友病A患者血浆,进行一步法FVIII活性和Bethesda抑制物测定。
  • 制备两种重组抗独特型单克隆抗体:rcAQ8靶向抗FIXa-Fab,rcAJ540靶向抗FX-Fab。

主要发现

  • 联合抗独特型单抗(各2000 nM)通过竞争性抑制抗体与FIX(a)/FX(a)结合,消除了艾美赛珠单抗对无抑制物或有抑制物血友病A血浆APTT的影响。
  • 在无抑制物血友病A血浆中,艾美赛珠单抗(1 μM = ~150 μg mL-1)存在时,所有参考水平的FVIII凝血活性测定均被高估。
  • 向测定混合物中加入抗艾美赛珠单抗单抗可完全中和艾美赛珠单抗,实现FVIII活性的准确测定。
  • 在有抑制物血友病A血浆或混合抗FVIII中和抗体的正常血浆中,艾美赛珠单抗存在时抗FVIII抑制物滴度不可检测。
  • 加入抗独特型单抗可完全抵消艾美赛珠单抗的这些效应,实现抑制物滴度的准确评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Emicizumab (Emi) affects the APTT-based assays of factor (F)VIII activity and inhibitor titer. A mixture of two anti-Emi monoclonal antibodies (mAb) effectively neutralized the Emi activity. Anti-Emi mAbs completely eliminated the influence of Emi on FVIII activity and inhibitor titer. The inclusion of anti-Emi mAbs in routine FVIII assays would be useful for Emi-treated patients. SUMMARY: Background Emicizumab is an anti-factor (F)IXa/X bispecific monoclonal antibody (mAb), mimicking the factor (F)VIIIa cofactor activity. Emicizumab does not require activation by thrombin and its shortening effect on the activated partial prothrombin time (APTT) is more pronounced than that of factor (F)VIII. APTT-based FVIII activity (FVIII:C) and FVIII inhibiter titer measurements are influenced by the presence of emicizumab. Aim To establish a reliable APTT-based assay to measure FVIII in the presence of emicizumab. Methods Plasmas from hemophilia A (HA) patients without or with inhibitors were studied using one-stage FVIII:C and Bethesda inhibitor assays. Two recombinant anti-idiotype mAbs to emicizumab (anti-emicizumab mAbs) were prepared, rcAQ8 to anti-FIXa-Fab and rcAJ540 to anti-FX-Fab. Results The combined anti-idiotype mAbs (2000 nm each) eliminated the effects of emicizumab on APTTs of HA plasmas without or with inhibitor by competitive inhibition of antibody binding to FIX(a)/FX(a). Measurements of FVIII coagulation activity in HA plasmas without inhibitor were overestimated in the presence of emicizumab (1 μm = ~150 μg mL-1 ) at all reference levels of FVIII. The addition of anti-emicizumab mAbs to the assay mixtures completely neutralized the emicizumab and facilitated accurate determination of FVIII:C. Anti-FVIII inhibitor titers were undetectable in the presence of emicizumab in HA plasmas with inhibitor or normal plasmas mixed with anti-FVIII neutralizing antibodies. These effects of emicizumab were completely counteracted by the addition of the anti-idiotype mAbs, allowing accurate assessment of inhibitor titers. Conclusion The in vitro inclusion of anti-emicizumab mAbs in the standard one-stage coagulation assays prevented interference by emicizumab and enabled accurate measurements of FVIII:C and inhibitor titers.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Nogami K, Soeda T, Matsumoto T, et al. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018. PMID: 29734520. doi:10.1111/jth.14135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。